Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
In 272 participants, mean (SD) age was 70 (4.5) years, 270 were male (99.3%), and 83 (30.5%) were amyloid-PET positive.
Why it matters
The p-tau217/Aβ42 ratio test was accurate in veterans without traumatic brain injury but missed many amyloid-PET-positive cases in those with traumatic brain injury with loss of consciousness. This is a caution about interpreting this blood test in that group, not a finding about treating or preventing Alzheimer's disease.
-
This study evaluates the quantile-aggregation method using both simulated data and publicly available Alzheimer disease randomized trial data.
Why it matters
This study looks at a statistical method for combining results in Alzheimer disease trials, using simulated data and existing trial data. It does not test any treatment in patients, so it does not show whether any therapy works.
-
Simufilam did not meet co-primary or secondary endpoints in these Phase 3 trials.
Why it matters
In two Phase 3 trials, RETHINK and REFOCUS, simufilam failed to meet its main or secondary goals for slowing decline in mild-to-moderate Alzheimer's. An early hint of benefit in a mild subgroup disappeared later and did not repeat in the other trial, though the drug was safe and well tolerated. These results do not support simufilam as an Alzheimer's treatment.
-
Plasma GFAP is a prognostic biomarker in CU older adults, predicting cognitive and biological changes, with stronger associations observed in females, highlighting a possible sex-specific vulnerability.
Why it matters
In 949 cognitively unimpaired older adults, higher baseline plasma GFAP predicted faster cognitive decline, increased risk of CDR progression, AD-related cortical atrophy, and amyloid conversion, with stronger effects in females. This identifies GFAP as a prognostic biomarker in cognitively unimpaired older adults, but it does not show that measuring or targeting GFAP prevents or treats Alzheimer's disease.
-
A total of 325 participants enrolled and received study drug.
Why it matters
In this phase III trial of 325 participants with early Alzheimer's disease who were APOEε4/ε4 homozygotes, the drug did not show significant effects on cognitive outcomes compared with placebo at 78 weeks, but did significantly slow hippocampal atrophy. In a prespecified mild cognitive impairment subgroup, nominally significant positive effects on some clinical measures were seen.
-
Using blood samples from the publicly available ADNI research cohort (191 people with mild cognitive impairment or dementia), this study found the PrecivityAD2 blood test agreed with amyloid PET scans about 91% of the time.
Why it matters
The PrecivityAD2 blood test matched brain PET scans 91% of the time in detecting amyloid pathology in 191 people with cognitive impairment. This diagnostic validation does not demonstrate whether identifying or treating amyloid improves symptoms or slows disease progression.
-
These findings suggest EPVS burden to be a potential marker of both CSVD and AD-related BBM pathology.
Why it matters
In 979 participants, a greater burden of enlarged perivascular spaces was linked to blood biomarkers of Alzheimer-related pathology and small vessel disease. This is a cross-sectional study, so it cannot show cause and effect or that acting on these findings prevents or treats Alzheimer's disease.
-
Mean (SD) β-glucocerebrosidase levels were higher at week 26 (ambroxol, 12.45 [1.97] nmol/h/mg; 91% CI, 11.54-13.36 nmol/h/mg); placebo, 8.50 [1.96] nmol/h/mg; 91% CI, 7.65-9.34 nmol/h/mg; P = .05) in the ambroxol group compared with placebo.
Why it matters
In this randomized trial of 55 patients with Parkinson disease dementia, ambroxol was safe, well-tolerated, and raised β-glucocerebrosidase levels compared with placebo. The study only showed this target engagement, not any effect on thinking or on Alzheimer's disease.
-
The discovery cohort contained 3,671 individuals with a mean age of 68 years and consisted of 49% reported female.
Why it matters
An FDG-PET-based machine learning framework detected 9 different neurodegenerative phenotypes with a sensitivity of 0.89 and an area under the curve of 0.93, and readers using the model had 3.3 times greater odds of making a correct diagnosis. This is a diagnostic support tool and does not treat, cure, or prevent Alzheimer's disease.
-
-fold changes of 1.21, 0.57, and 4.63, respectively, compared to A-.
Why it matters
A targeted proteomics panel detected proteins linked to Alzheimer's and related dementias, including pTDP43-409, which correlated with declining hippocampal volume and cognitive trajectories. The authors state that the promising pTDP43-409 findings require further replication.
-
(69.4% female) were aged 68.3 ± 5.1 years at their first PET scans.
Why it matters
Among cognitively unimpaired people with a parent who had Alzheimer's disease, women showed greater tau deposition and a stronger link between amyloid and tau than men. Women and those with an affected father seemed more vulnerable to the amyloid-related spread of tau, though the study had a reduced sample for the analyses based on which parent was affected.
-
58/100
Of the total of 1795 subjects randomized in Clarity AD, 294 subjects were in the Asian region (Japan:152; Korea:129; Singapore:13).
Why it matters
In the Asian region portion of the phase III Clarity AD trial (294 of 1795 participants), lecanemab slowed decline on the CDR-SB at 18 months compared with placebo, with a safety profile similar to the overall trial population. This supports lecanemab's use in early Alzheimer's disease but does not show it cures or prevents the disease.
-
However, a recent systematic review and meta-analysis did not support differences in orexin-A between AD and controls.
Why it matters
This study tested whether spinal fluid orexin-A relates to Alzheimer's biomarkers and cognitive performance in older adults with and without symptomatic disease. It is an observational biomarker study and does not test any treatment.
-
This study provides a comprehensive review of the last 10 years of research on neuroinflammation and AD, including the number and impact of research findings, research hotspots, and future trends.
Why it matters
This bibliometric analysis mapped 3,833 publications on brain inflammation and Alzheimer's from 2014 to 2024, finding most came from the United States and China. Research hotspots centered on microglia, the brain's immune cells, mouse models, oxidative stress and amyloid-beta, with the blood-brain barrier and tau protein gaining attention recently. It describes research trends rather than new findings, pointing to calming microglia's inflammatory responses as a direction for future work.
-
We aim to investigate the relationships between the population characteristics of patients with Alzheimer's Disease (AD) and their Healthcare Utilization (HU) during the COVID-19 pandemic.
Why it matters
This study examined characteristics of older adults with Alzheimer's disease who were hospitalized during the COVID-19 pandemic. It reports factors associated with longer stays and higher hospitalization frequency, and does not test any treatment, cure, or prevention.
-
The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau 217 showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Why it matters
In plasma samples from people in a memory clinic, pTau217 and pTau181 were higher and the Aβ42/40 ratio lower in those with amyloid positivity on CSF testing. This concerns a blood test for detecting brain amyloidosis, not treating, curing or preventing Alzheimer disease.
-
Research evidence indicating common metabolic mechanisms through which type 2 diabetes mellitus (T2DM) increases risk of late-onset Alzheimer's dementia (LOAD) has accumulated over recent decades.
Why it matters
This review looked for shared biology between type 2 diabetes and late-onset Alzheimer's, evaluating 923 publications and pulling out 138 gene loci as possible shared risk links. The overlap centred on insulin signalling, inflammation, energy and fat metabolism, and the cell's waste-disposal (autophagy) pathways. The authors say this points to an interplay between brain insulin resistance and inflammation, and should help design more focused long-term studies.
-
This comprehensive analysis demonstrated that the variance in AD blood biomarker concentrations was mainly explained by age, with minor contributions from cognition, brain atrophy, and genetics, conversely to CSF measures.
Why it matters
This analysis found that age explained most of the variation in Alzheimer's blood biomarker levels, with only minor contributions from cognition, brain atrophy, and genetics. The authors conclude that blood biomarkers should not be used as stand-alone tests, and the study does not address treatment, cure, or prevention.
-
58/100
A diverse and stable microbiota promotes a healthy state, nevertheless, an imbalance in gut or oral bacterial composition, called dysbiosis, can cause gastrointestinal disorders, systemic inflammatory states and oxidative stress, among others.
Why it matters
This review examines how an imbalance in gut or mouth bacteria may feed the brain inflammation seen in Alzheimer's. It describes a leaky gut barrier letting bacterial products into the blood and activating immune cells in the brain, and notes that the mouth bacterium Porphyromonas gingivalis in the brain can increase inflammation and beta-amyloid build-up. It summarizes proposed mechanisms rather than testing any treatment.
-
Disease-modifying drug use necessitates better Alzheimer disease (AD) detection.
Why it matters
This 4-year biomarker study in ADNI and MEMENTO examined whether adding mild behavioral impairment to mild cognitive impairment better identifies Alzheimer's disease using CSF biomarkers. It is an observational detection study and does not test any treatment, cure, or prevention.
-
This randomized controlled trial aims to investigate the effect of 12 weeks of therapeutic exercise on cognitive function and daily activities in patients with mild Alzheimer's disease (AD).
Why it matters
In people with mild Alzheimer disease, 12 weeks of aerobic plus resistance exercise or resistance exercise alone improved cognitive function and daily activities compared with no exercise. There was no significant difference between the two exercise groups.
-
While plasma biomarkers for Alzheimer's disease (AD) are increasingly being evaluated for clinical diagnosis and prognosis, few population-based autopsy studies have evaluated their utility in the context of predicting neuropathological changes.
Why it matters
In a population-based study of 350 participants with autopsy and antemortem plasma testing, Alzheimer's disease neuropathologic change was best predicted by plasma GFAP, NfL, and p-tau181 along with APOE ε4 carrier status and a cognitive score, with a cross-validated AUC of 0.798. GFAP and p-tau provided non-overlapping information on neuritic plaque and Braak stage scores while Aβ42/40 and NfL were mainly useful for predicting neuritic plaque scores, but this concerns prediction of pathology rather than treatment, cure, or prevention.
-
58/100
Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia.
Why it matters
This review reports that Alzheimer's disease is highly heritable, with heritability estimated at about 70% from twin studies, and that larger genetic studies have greatly increased the number of known disease susceptibility loci. It does not describe a treatment or cure; it indicates that genetic research is expanding knowledge of who may be at risk and why.
-
The MIND and Mediterranean diets are associated with less postmortem AD pathology, primarily β-amyloid load.
Why it matters
In 581 autopsied participants, higher MIND and Mediterranean dietary pattern scores were associated with lower global Alzheimer's disease pathology. This is an observational association in older adults and does not prove that these diets prevent or treat Alzheimer's disease.
-
Our results support the positive cognitive effects of boswellic acids by reducing the systemic inflammation.
Why it matters
In a 6-month double-blind trial of 85 people with mild to moderate Alzheimer's disease, those given boswellic acids (K-Vie, the main ingredient in Memowell) improved by 3.1 units on the MMSE and 1.6 units on the CDR-SOB compared with placebo, and had lower levels of inflammatory signals such as IL-6 and TNF. Only mild stomach side effects were reported in a few patients. The authors say this supports a cognitive benefit tied to reducing body-wide inflammation, based on this one trial of 85 patients.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
- Inflammatory Processes in Alzheimer's Disease-Pathomechanism, Diagnosis and Treatment: A Review
- Privación del Sueño y Melatonina Factores que Influyen en la Enfermedad de Alzheimer: Revisión Sistemática
- Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid
- Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine
- Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported
- Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease
- HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier
- Association between advanced glycation end-products and functional performance in Alzheimer's disease and mixed dementia
- Alzheimer Disease and the Utility of PET